Arvinas, Inc. Common Stock ARVN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T15:59:54.785Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:58:22.633337387Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T15:59:53.243565+00:00
Arvinas, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 6.14 | 67.2% | 11.0% | |||
| 25Δ | 6.23 | 63.6% | 10.0% | |||
| 30Δ | 6.31 | 60.0% | 8.9% | |||
| 35Δ | 6.40 | 56.4% | 7.9% | |||
| 40Δ | 6.49 | 52.8% | 6.9% | |||
| 45Δ | 6.58 | 49.2% | 5.8% | |||
| 50Δ | 6.67 | 45.7% | 4.8% | |||
| 55Δ | 6.76 | 42.1% | 3.8% | |||
| 60Δ | 6.84 | 38.5% | 2.7% | |||
| 65Δ | ||||||
| 70Δ | 5.95 | 319.3% | 13.0% | 8.43 | 196.4% | 5.3% |
| 75Δ | 5.57 | 299.1% | 9.8% | |||
| 80Δ | 5.20 | 279.0% | 6.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.14
- IV
- 67.2%
- B/E move
- 11.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.23
- IV
- 63.6%
- B/E move
- 10.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.31
- IV
- 60.0%
- B/E move
- 8.9%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.40
- IV
- 56.4%
- B/E move
- 7.9%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.49
- IV
- 52.8%
- B/E move
- 6.9%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.58
- IV
- 49.2%
- B/E move
- 5.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.67
- IV
- 45.7%
- B/E move
- 4.8%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.76
- IV
- 42.1%
- B/E move
- 3.8%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.84
- IV
- 38.5%
- B/E move
- 2.7%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 5.95
- IV
- 319.3%
- B/E move
- 13.0%
- Pseudo strike
- 8.43
- IV
- 196.4%
- B/E move
- 5.3%
75Δ
- Pseudo strike
- 5.57
- IV
- 299.1%
- B/E move
- 9.8%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 5.20
- IV
- 279.0%
- B/E move
- 6.7%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 88.98% | |
| 70.69% | |
| 76.59% | |
| 101.31% | |
| 106.76% | |
| 108.44% | |
| 96.78% | |
| 101.08% | |
| 93.14% | |
| 99.81% |
Biotechnology
ARWR
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
More →ASMB
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
More →ASND
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
More →ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation (BMT) or a type of…
More →ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered…
More →AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is…
More →